New chemotherapy agents in veterinary medicine

Veterinary Clinics of North America - Small Animal Practice

Volumn 33, Issue 3, 2003, Pages 629-649

  Moore, Antony S ^a   Kitchell, Barbara E ^b  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BUTORPHANOL; CARBOPLATIN; CHLORMETHINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; GEMCITABINE; GLUCOSE; IFOSFAMIDE; LOMUSTINE; MESNA; METHYLNITROSOUREA; NEW DRUG; NITROSOUREA DERIVATIVE; NUCLEOSIDE ANALOG; ONDANSETRON; OXAZAPHOSPHORINE DERIVATIVE; PLATINUM DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT; RINGER LACTATE SOLUTION; STREPTOZOCIN; SULFADIAZINE; TRIMETHOPRIM; UNINDEXED DRUG;

ANIMAL DISEASE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CAT; DOG; DRUG ABSORPTION; DRUG CAPSULE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HYPOGLYCEMIA; NONHUMAN; REVIEW; SINGLE DRUG DOSE; VETERINARY MEDICINE; VOMITING;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0037742207     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-5616(03)00033-0     Document Type: Review

References (66)

1. Olivero VT. Pharmacology of the nitrosoureas: an overview. Cancer Treat Rep 1976;60:703-7.
2. Tuvesson H, Gunnarsson PO, Seidegard J. Measurement and characterization of the denitrosation of tauromustine and related nitrosoureas by glutathione transferases in liver cytosol from various species. Carcinogenesis 1993;14:1143-7.
3. Carter SK, Newman JW. Nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962; BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC-79037; CCNU)-clinical brochure. Cancer Chemother Rep 1968;1:115-51.
4. Schaeppi U, Fleischmann RW, Phelan RS, et al. CCNU 9NSC-79037: preclinical toxicologic evaluation of a single intravenous infusion in dogs and monkeys. Cancer Chemother Rep 1974;5:53-64.
5. Abb J, Netzel B, Rodt HV, et al. Autologous bone marrow grafts in dogs treated with lethal doses of 1(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res 1978;38:2157-9.
6. Henry MC, Davis RD, Schien PS. Hepatotoxicity of 1(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs. Toxicol Appl Pharmacol 1973;25:410-7.
7. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of relapsed lymphoma in dogs. J Vet Intern Med 1999;13:395-8.
8. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU. J Vet Intern Med 1999;13:601-5.
9. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. Submitted.
10. Fulton LM, Steinberg HS. Preliminary study of lomustine in the treatment of intracranial masses in dogs following localization by imaging techniques. Semin Vet Med Surg (Small Anim) 1990;5:241-5.
11. Graham JC, Myers RK. Pilot study on the use of lomustine (CCNU) for the treatment of cutaneous lymphoma in dogs [abstract]. J Vet Intern Medicine 1999;13:257.
12. Rassnick KM, Geiger TL, Williams LE, et al. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats. J Vet Intern Med 2001;15:196-9.
13. Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 1982;9:313-30.
14. Fan TM, Kitchell BE, Dhaliwal RS, et al. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: a critical assessment of a practical dosing regimen. J Am Anim Hosp Assoc 2002;38:357-63.
15. Ikeda K, Inoue N, Frassica FJ, et al. Development of a canine chemotherapeutic model with ifosfamide. Lab Anim Sci 1996;46:503-6.
16. Barnett D. Preclinical toxicology of ifosfamide. Semin Oncol 1982;9(Suppl 1):8-13.
17. Brock N, Pohl J, Stekar J, et al. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 1982;18:1377-87.
18. Rassnick KM, Frimberger AE, Wood CA, et al. Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med 2000;14:271-6.
19. White FR. Streptozotocin. Cancer Chemother Rep 1963;30:49-53.
20. Tew KD, Colvin M, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott-Raven; 1996. p. 297-332.
21. Stolinsky DC, Sadoff L, Braunwald J, et al. Streptozotocin in the treatment of cancer: phase II study. Cancer 1972;30:61-6.
22. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:108-18.
23. Schein PS, O'Connell MJ, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 1974;34:993-1000.
24. Handelsman H, Broder LE, Slavik M, et al. Streptozotocin NSC-85998. Clinical brochure. Investigational Drug Branch, Cancer Therapy Evaluation, Division of Cancer Treatment, National Cancer Institute; 1974. p. 1-68.
25. Levine BS, Henry MC, Port CD, et al. Toxicologic evaluation of streptozotocin (NSC 85998) in mice, dogs and monkeys. Drug Chem Toxicol 1980;3:201-12.
26. Kaneko JJ, Mattheeuws D, Rottiers RP, et al. Renal function, insulin secretion, and glucose tolerance in mild streptozotocin diabetes in the dog. Am J Vet Res 1978;39: 807-9.
27. Gans JH, Cater MR. Hypercholesterolemia of streptozotocin-induced diabetes mellitus in dogs. Life Sci 1971;10:301-8.
28. Meyer DJ. Pancreatic islet cell carcinoma in a dog treated with streptozotocin. Am J Vet Res 1976;37:1221-3.
29. Meyer DJ. Temporary remission of hypoglycemia in a dog with an insulinoma after treatment with streptozotocin. Am J Vet Res 1977;38:1201-4.
30. Moore AS, Nelson RW, Henry CJ, et al. Streptozotocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999). J Am Vet Med Assoc 2002;221:811-8.
31. Moore AS, Rand WM, Berg J, et al. Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs. J Am Vet Med Assoc 1994;205:441-3.
32. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Ocol 1997;15:2403-13.
33. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-8.
34. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533-9.
35. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31.
36. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
37. Xu YZ, Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1992;44:1819-27.
38. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001;15:875-90.
39. Schiller JH, Harrington D, Belani CP, et al. The Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced nonsmall cell lung cancer. N Engl J Med 2002;346:92-8.
40. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002;95:941-5.
41. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
42. Seidman AD. The evolving role of gemcitabine in the management of breast cancer. Oncology 2001;60:189-98.
43. Nabhan C, Krett N, Gandhi V, et al. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13:514-21.
44. Spath-Schwalbe E, Genvresse I, Koschuth A, et al. Phase II trial of gemcitabine in patients with pretrated advanced soft tissue sarcomas. Anticancer Drugs2000;13(11):325-9.
45. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000;45:177-81.
46. Plunkett W, Gandhi V. Nucleoside analogs: cellular pharmacology, mechanisms of action, and strategies for combination therapy. In: Cheson B, Keating JM, Plunkett W, editors. Nucleoside analogs in cancer therapy. New York: Marcel Dekker Inc.; 1997. p. 1-35.
47. Millikan RE, Plunkett WK, Smith TL, et al. Gemcitabine modulation of alkylator therapy. A phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer 2001;92:194-9.
48. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin 2001;19(3):792-9.
49. Lawrence TS, Eisbburch A, McGinn CJ, et al. Radiosensitization by gemcitabine. Oncology 1999;13(Suppl 5):55-69.
50. Doyle TH, Mornex F, McKenna WG. The clinical implications of gemcitabine radiosensitization. Clin Cancer Res 2001;7:226-8.
51. Shipley LA, Brown TJ, Cornpropst JD, et al. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 1992;20:849-55.
52. Esumi Y, Mitsugi K, Takao A, et al. Disposition of gemcitabine in rat and dog after single and multiple dosings. Xenobiotica 1994;24:805-17.
53. Cozzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999;5:2629-37.
54. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 1997;24(Suppl 7):2-7.
55. Boyce KL, Kitchell BE. Gemcitabine single agent for the treatment of advanced cancer in the dog and cat: a pilot study. Proc Vet Cancer Soc Ann Meeting 1998;18:24.
56. Walter CU, Shaw NG, LaDue TA. Gemcitabine in the treatment of refractory or recurrent canine lymphoma. Proc Vet Cancer Soc Ann Meeting 2001;21:46.
57. Kisseberth WE, Kosarek CE, Couto CG. Phase I evaluation of gemcitabine (Gemzar) in tumor-bearing dogs. Proc Vet Cancer Soc Ann Meeting 2002;22:7.
58. Marconato L, Lindner DL, Suslak-Brown L, et al. A phase I clinical trial of high-dose gemcitabine in 33 dogs with transitional cell carcinoma. Proc Vet Cancer Soc Ann Meeting 2002;22:9.
59. LaDue TA, Klein MK. What is a radiosensitizer (?): update on gemcitabine for canine sinonasal carcinoma and feline oral squamous cell carcinoma. Proc Am College of Veterinary Radiologist Annual Scientific Meeting, 2002.
60. 2 per min) and cisplatin. Cancer Chemother Pharmacol 2002;50:80-3.
61. Kroep JR, Peters GJ, Van Moorsel CJ, et al. Gemcitabine - cisplatin: a schedule finding study. Ann Oncol 1999;10:1503-10.
62. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2′,2′-difluorodeoxycytidine 5′triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-62.
63. Gandhi V, Plunkett W, Du M. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous luekemia. J Clin Oncol 2002;20:665-73.
64. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8.
65. Aapro MS, Martin C, Hatty S. Gemcitabine-a safety review. Anticancer Drugs 1998;9:191-201.
66. Jones PD, deLorimier LP, Kitchell BE, et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc, in press.